Drugs / MnB rLP2086
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00297687 | Mar 2006 → Mar 2007 | meningococcal meningitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MnB rLP2086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00297687 ↗ |
| Modality | Vaccine | “A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in...” NCT00297687 ↗ |